Learn about cutting-edge science and gain life-enhancing insights.


atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profile Pharmacokinetic and pharmacodynamic…


atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia. GRX-917: Presented PD…


atai Life Sciences to Participate in Upcoming May Investor Conference

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to…


atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

– Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines NEW…


atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to…


atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living…

Press Inquiries

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Headquartered in Berlin, with offices in New York and London, our vision is to heal mental health disorders so that everyone everywhere can live a more fulfilled life.


Receive the latest news on atai and innovations in the space.